文献速递胸部肿瘤放疗放疗物理与技术

连续治疗前18F-FDG PET-CT指标升高预测接受立体定向消融放疗的早期非小细胞肺癌患者生存

Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2018-11-26

本研究回顾性分析143例早期非小细胞肺癌患者共152个病灶,在接受立体定向消融放疗(SABR)前进行连续PET-CT检查,计算代谢肿瘤生长速率(MTGR)和最大标准化摄取值速度(SUV V)。结果显示MTGR大于0.04 mL/d与死亡风险相关,在发现队列(P=0.048)和验证队列(P<0.01)中均有预后价值;SUV V升高与复发和死亡风险呈非显著趋势。

要点

  • MTGR大于0.04 mL/d可预测接受SABR的早期非小细胞肺癌患者死亡。
  • SUV V升高与复发和死亡风险增加呈非显著趋势。
  • MTGR和SUV V可能是评估SABR联合系统治疗试验的候选影像生物标志物。

核心结论

  • MTGR大于0.04 mL/d对接受SABR的非小细胞肺癌患者死亡具有预后价值。
  • SUV V升高与复发和死亡风险增加呈非显著趋势。
  • MTGR和SUV V可能是评估SABR联合系统治疗高危野外复发患者的试验中的候选影像生物标志物。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准,纳入在诊断分期和SABR模拟定位时接受PET-CT的患者。
  • 发现队列于2005年11月至2012年10月接受SABR,验证队列于2012年1月至2016年4月接受SABR。
  • 共143例患者152个病灶,其中发现队列83例患者92个病灶。
  • MTGR和SUV V分别计算为代谢肿瘤体积和最大标准化摄取值的每日变化。
  • 采用Cox比例风险模型识别局部、区域、远处复发和死亡的预测因素。

主要发现

  • 在多变量模型中,MTGR升高与远处复发风险增加呈趋势(风险比6.98;95%置信区间0.67-72.61;P=0.10)。
  • 在单变量模型中,SUV V与死亡风险呈趋势(风险比11.8;95%置信区间0.85-165.1;P=0.07)。
  • MTGR大于0.04 mL/d在发现队列(P=0.048)和验证队列(P<0.01)中均与生存期缩短相关。

关键数值与推荐

  • MTGR大于0.04 mL/d为预后不良的阈值,在发现队列P=0.048,验证队列P<0.01。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Quantitative changes in positron emission tomography with computed tomography imaging metrics over serial scans may be predictive biomarkers. We evaluated the relationship of pretreatment metabolic tumor growth rate (MTGR) and standardized uptake value velocity (SUVV) with disease recurrence or death in patients with early-stage non-small cell lung cancer treated with stereotactic ablative radiation therapy (SABR). METHODS AND MATERIALS: Under institutional review board approval, we retrospectively identified patients who underwent positron emission tomography with computed tomography at diagnosis and staging and simulation for SABR. Two cohorts underwent SABR between November 2005 to October 2012 (discovery) and January 2012 to April 2016 (validation). MTGR and SUVV were calculated as the daily change in metabolic tumor volume and maximum standardized uptake value, respectively. Cox proportional hazard models identified predictors of local, regional, and distant recurrence and death for the combined cohort. MTGR and SUVV thresholds dichotomizing risk of death in the discovery cohort were applied to the validation cohort. RESULTS: A total of 152 lesions were identified in 143 patients (92 lesions in 83 discovery cohort patients). In multivariable models, increasing MTGR trended toward increased hazard of distant recurrence (hazard ratio, 6.98; 95% confidence interval, 0.67-72.61; P = .10). In univariable models, SUVV trended toward risk of death (hazard ratio, 11.8, 95% confidence interval, 0.85-165.1, P = .07). MTGR greater than 0.04 mL/d was prognostic of decreased survival in discovery (P = .048) and validation cohorts (P < .01). CONCLUSIONS: MTGR greater than 0.04 mL/d is prognostic of death in patients with non-small cell lung cancer treated with SABR. Increasing SUVV trends, nonsignificantly, toward increased risk of recurrence and death. MTGR and SUVV may be candidate imaging biomarkers to study in trials evaluating systemic therapy with SABR for patients at high risk of out-of-field recurrence.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Prionas ND, von Eyben R, Yi E, et al. Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. Adv Radiat Oncol. 2018. PMID: 31011689. doi:10.1016/j.adro.2018.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。